ARS Pharmaceuticals Stock Forecast
NASDAQ: SPRYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
SPRY analyst consensus
Consensus (4 analysts)
none
Avg. price target
$22.50+416.06%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering ARS Pharmaceuticals (2026-10-08), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $22.50, with a high estimate of $30.00 and a low estimate of $15.00. The average target implies upside of 416.1% from the current price of $4.36.
The spread between the highest and lowest targets is 100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SPRY.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $15.00 | +244.04% |
| Average target | $22.50 | +416.06% |
| High target | $30.00 | +588.07% |